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Abstract
Background: Falls are common undesirable events for older adults in institutions. Even though the patient’s fall risk
may be scored on admission, the medication-induced fall risk may be ignored. This study developed a preliminary
categorization of fall-risk-increasing drugs (FRIDs) to be added as a risk factor to the existing fall risk assessment tool
routinely used in geriatric care units.
Methods: Medication use data of older adults who had experienced at least one fall during a hospital ward or a
nursing home stay within a 2-year study period were retrospectively collected from patient records. Medicines used
were classified into three risk categories (high, moderate and none) according to the fall risk information in
statutory summaries of product characteristics (SmPCs). The fall risk categorization incorporated the relative
frequency of such adverse drug effects (ADEs) in SmPCs that were known to be connected to fall risk (sedation,
orthostatic hypotension, syncope, dizziness, drowsiness, changes in blood pressure or impaired balance). Also,
distribution of fall risk scores assessed on admission without considering medications was counted.
Results: The fall-experienced patients (n = 188, 128 from the hospital and 60 from nursing home records) used
altogether 1748 medicaments, including 216 different active substances. Of the active substances, 102 (47%) were
categorized as high risk (category A) for increasing fall risk. Fall-experienced patients (n = 188) received a mean of
3.8 category A medicines (n = 710), 53% (n = 375) of which affected the nervous and 40% (n = 281) the
cardiovascular system. Without considering medication-related fall risk, 53% (n = 100) of the patients were scored
having a high fall risk (3 or 4 risk scores).
Conclusion: It was possible to develop a preliminary categorization of FRIDs basing on their adverse drug effect
profile in SmPCs and frequency of use in older patients who had experienced at least one documented fall in a
geriatric care unit. Even though more than half of the fall-experienced study participants had high fall risk scores on
admission, their fall risk might have been underestimated as use of high fall risk medicines was common, even
concomitant use. Further studies are needed to develop the FRID categorization and assess its impact on fall risk.
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Background
Falls constitute a leading preventable cause of geriatric
injuries and hospitalization, prolonged recovery times
and deaths [1, 2]. More than a third of older adults fall
each year, meaning worldwide a high number of patients
[3]. Fall-related injuries can be serious, occuring ap-
proximately in 10% of falls, and consequencing an ur-
gent hospitalization [3, 4]. Furthermore, falls decrease
self-sufficiency and quality of life among older adults,
because falls can result in fear of falling, loss of confi-
dence, mobility and ability to live independently [5].
Fall risk is a multifactorial problem associated with nu-
merous intrinsic and extrinsic factors [6, 7]. Intrinsic
factors are related to ageing, including age-related
changes to the pharmacokinetic and pharmacodynamic
effects of pharmacotherapies. Age-related pharmacoki-
netic changes are represented by drug absorption, distri-
bution, metabolism and elimination route. The drug
absorption is usually decreased due to changes in the
gastrointestinal tract, e.g., reduced gastric secretion, loss
of mucosal intestinal surface and decreased blood flow
in splanchnic area. The drug distribution is affected by
many factors, e.g., increase in fat compartment, decrease
in total body water, muscle mass and serum albumin
level. The distribution volume of water soluble drugs is
decreased leading to their potential toxicity, while the
distribution volume of lipid soluble drugs is increased
leading to prolongation of elimination half-life and accu-
mulation of the drug in fatty tissues. The drug metabo-
lism is influenced by decreased hepatic blood flow and
low activity of liver enzymes. The elimination route is
limited due to reduction in renal clearance [7, 8]. Phar-
macodynamic changes involve altered sensitivity to
many pharmacological agents, increased sensitivity in
psychotropic or cardiovascular drugs, in contrast with
decreased capacity to respond to physiological challenges
and side effects of the drug therapy, e.g., orthostatic
hypotension [1, 9].
Extrinsic factors include fall risks related to the environ-
ment where individuals live, e.g., how medicines are taken
at home [6, 10]. Prescribed medication is an important
and potentially underappreciated contributor to falls [11,
12]. The older adults are susceptible to polypharmacy and
higher risk of falls [13]. Polypharmacy can increase the
risk of medication-related falls, especially when at least
one established fall risk-increasing drug is part of the pa-
tient’s daily regimen [14]. A leading mechanism for in-
creased risk can be sedation which slows reaction time,
orthostatic hypotension, syncope, dizziness, drowziness,
and blood pressure change or impaired balance [15]. Nor-
mally, long-acting medications pose a higher risk, but the
metabolism and half-life of otherwise short-acting drugs
can be also prolonged in older adults [16, 17]. Previous
studies have presented various methods reducing fall risks
in older adults, such as supplementation of vitamin D and
calcium, cataract surgery, hip protectors, modification of
hazard environment and adjustment of medications [18,
19]. In addition, stability of the human body is a crucial
factor for reducing falls [20]. Recommended actions to im-
prove stability include exercise programs focusing on bal-
ance and muscle strength [21]. There is a good evidence
for reducing medication-induced falls. In psychotropics,
the fall risk can be reduced by prospective management of
adverse effects such as drowsiness, dizziness, slow reaction
time and orthostatic hypotension [22, 23]. Drugs reducing
blood pressure are associated with fall risk because of their
hypotension effect. Thus, adjusting anti-hypertensive
medication may reduce syncope and falls [24, 25]. The fall
risk prevention with anticoagulants should focus on bleed-
ing events such as a cerebral hemorrhage and associated
falls [26]. Many drugs disturb vision and vestibular system,
which exacerbate gait disturbance in older adults [27, 28].
In case of falls, reduced bone mineral density and osteo-
porosis can increase risk of fracture and more severe con-
sequences [29].
Evidence on medication-related fall risks is not always
integrated into multifactorial risk assessments which
contribute to preventive programmes for reducing falls
[30, 31]. Incorporating these risks could improve accur-
acy of existing tools routinely used in geriatric care units
as many of the current workflows do not contain medi-
cation as a risk factor [32]. This study aimed to provide
a better screen on falls in institutions by developing a
preliminary categorization of fall-risk-increasing drugs
(FRIDs) that could be added as a risk factor to the exist-




The patient data used in this study were retrospectively
derived from two different types of health care institu-
tions, i.e., a hospital and a nursing home in Brno, Czech
Republic. Medication data on all patients who had fallen
at least once during their stay at a health care institution
(hospital or nursing home) within a 2-year observational
period were derived from patient records. The fall is de-
fined by World Health Organization as an event which
results in a person coming to rest inadvertently on the
ground or floor or other lower level [31]. The falls dur-
ing a stay at a health care institution were documented
as undesirable events in a protocol, which contained
information about circumstances of the fall such as a de-
scription of fall, exact time and place, and consequences,
e.g., severe injuries, bone fracture or head injury, bruises
or bleeding risk. Descriptive and demographic informa-
tion on patients (sex, age, length of stay, MMSE score
and medication use) were collected from the patient
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records. Inclusion criteria of the study participants were
1) age ≥ 60 years old, 2) evidence of at least one fall dur-
ing their stay in a geriatric care unit, 3) evidence of fall
documented by health care professionals (nurses, physi-
cians). Exclusion criteria were 1) age < 60 years old, 2)
absence of falls during their stay in a geriatric care unit,
3) no evidence of falls documented by health care pro-
fessionals. The nursing home had less descriptive re-
cords of their residents, e.g., they missed a cognitive
impairment scale.
Developing categorization of medicines increasing fall
risk (FRIDs)
The medication-related fall risk was determined by
categorizing all medicines patients used according to
each medicine’s fall risk. The criteria for this
categorization was derived from the staturory sum-
maries of product characteristics (SmPCs) approved
by authorities as part of marketing authorization
within European Union countries [33]. The SmPC
information of each medicine was systematically
reviewed by two researchers (JM, KV) to derive the
fall risk. We applied information on a direct connec-
tion between the fall risk and adverse drug effects
(ADEs) disturbing the patient’s balance as presented in
SmPCs. This information was used to create an A, B, C
medication-related fall risk categorization. Usually the
mechanism leading to medication-related fall risk is one
or more of the following adverse drug effects: sedation,
orthostatic hypotension, syncope, dizziness, drowsiness,
changes in blood pressure or impaired balance [34, 35].
All these adverse drug effects have a negative influence
on a patient’s balance, which can then predispose the
patient to falls [36].
Adverse drug effects posing fall risk are classified in
the SmPC as very common (≥1/10), common (≥ 1/100),
uncommon (≥ 1/1000), rare (≥ 1/10000) and very rare
(< 1/10000) (Table 1). Medicines with at least one of the
above-mentioned adverse drug effect frequencies of
“very common” or “common” in the SmPC were catego-
rized as high fall risk medicines (category A). Similarly,
the medicines with an adverse drug effect frequency “un-
common” were categorized as moderate fall risk
medicines (risk level B) and those with rare or very rare
frequency as no fall risk medicines (risk level C). The
high-risk category A medicines are considered as a pre-
disposition factor to fall, because the occurrence of ad-
verse drug effects connected to falls is documented by at
least one patient per each 100 patients using the same
active substance. The risk information provided in the
SmPC of the brand product used by the patients
involved in the study was validated by comparing the
information with the SmPC information of another
similar product on the market.
Frequency of use of high fall risk medicines in study
participants with a fall history
The second phase of the study focused on counting the
frequency of use of high fall risk medicines in study par-
ticipants with a fall history in institutions. This phase
made use of the existing routine practice at the time of
the study of assessing and scoring all patients for fall risk
by nurses in the routine admission procedure. Both in-
stitutions used the same set of 4 risk items other than
medications to estimate fall risk (Table 2). The original
Morse Fall Score [37] had been shortened to a time-
saving procedure of 4 items suitable for clinical practice.
Each fall risk item yielded 1 point and they assessed 1)
history of falls, 2) mental condition, 3) physical condi-
tion, and 4) occurrence of dizziness or drowsiness in
older patients. The estimation was based on patient in-
terviews on admission or notes from patient records.
Direct questions to the patient were dependent on the
patient’s health condition. As this fall risk estimation did
not consider patient’s medication as a contributor to the
fall risk, the patient data on medication use were retro-
spectively collected from the patient records by the re-
searcher (JM). All the medicines were classified into
three risk categories (high, moderate and none) using
the new categorization based on the fall risk information
in the SmPCs. For the descriptive feasibility testing, the
medication data of the patients in the hospital and nurs-
ing home were combined to provide the widest possible
coverage of medicines used by older adults in
institutions.
Table 1 Fall risk level criteria: categorization according to information derived from the summaries of product characteristics (SmPC)
on the frequency of adverse drug effects (ADEs) contributing to fall risk (sedation, orthostatic hypotension, syncope, dizziness,
drowsiness, changes in blood pressure or impaired balance)
Frequency of ADEs Number of patients experiencing ADEs Fall risk level
Very common ≥ 1/10 A
Common ≥ 1/100 to < 1/10 A
Uncommon ≥ 1/1000 to < 1/100 B
Rare ≥ 1/10000 to < 1/1000 C
Very rare < 1/10000 C
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Statistical analysis
Descriptive statistics were used in both study phases
to categorize active substances according to their fall
risk, and to test the categorizations with a retrospect-
ive sample of patients from a secondary care hospital
and a nursing home. All patients were grouped to-
gether for the analysis. Data were processed in Micro-
soft Excel, version 2016. A pivot table was created to
analyze worksheet data. Descriptive statistics were
used for patient data to count metric items such as
frequencies, means, ranges, and standard deviations.
The categorization of medicines according to their fall
risk used ATC codes, specified in levels of anatomical
main group, therapeutic subgroup, and pharmaco-
logical subgroup [38]. The commonly used active sub-
stances in the high fall risk category A were




In total 188 fall-experienced older patients were retro-
spectively drawn from the patient registers of both insti-
tutions included in this study covering the 2-year period
from January 2016 to December 2017 (Table 3). Of the
patients, 128 (68%) were from the geriatric department
of a secondary care hospital and 60 (32%) from a nursing
home. Of them, 103 were females and 85 males with the
mean age of 79 years (range: 60–97 years, standard devi-
ation ±18.5). They used on average 9.3 medicaments
(range: 2–17, standard deviation ±7.5) during a stay in a
health care institution. The mean length of stay of the
study patients in the secondary care hospital (n = 128)
was 15.8 days (range: 1–56 days, standard deviation ±
27.5). The most common causes of hospitalization were
cardiovascular problems, and/or respiratory and urogeni-
tal tract infections. The half (52%) of the patients had at
least a mild cognitive impairment (≤ 23 points), the mean
score in the Mini Mental State Exam (MMSE) being 21.7
points (range: 5–30 points, standard deviation ±12.5). The
stay for nursing home residents (n = 60) was permanent.
Data about their cognitive function was not available.
They suffered from many chronic diseases (cardiac, neuro-
logic) and used chronic long-term medications.
The fall risk scores of study participants assessed on
admission
Medications were not included in the routinely used as-
sessment. Nurses had assessed and scored all patients
(n = 188) for fall risk on admission using the original 4
risk items (score range 0–4). This fall risk assessment is
a part of the regular procedure in each patient admis-
sion. More than half (53%, n = 100) of the patients were
scored as having at least high fall risk (had 3 or 4 risk
scores), the remaining patients (46%, n = 88) being
scored with medium or lower risk (Table 4).
Categorization of medicines according to their fall risk by
applying SmPCs and frequency of use
Fall-experienced patients (n = 188) used altogether 1748
medicaments. Of these medicaments, 710 (41%)
belonged to the category of high fall risk (category A),
331 (19%) moderate risk (category B) and 707 (40%) no
risk (category C). The mean number of high-risk medi-
cations (category A) in use per patient was 3.8 medica-
tions, minimum 0 (n = 2), maximum 8 (n = 4) and
median being 3 (n = 46). The majority (93%) of high-risk
category A medicines (n = 710) used by the patients were
Table 2 The items included in the existing fall risk estimation routinely used in the two health care institutions participating in the
study (a hospital and a nursing home)
Fall risk item Responsible person Confirmation Points in the scale
Evidence of fall during a month prior the assessment nurse ✓ 1
Confusion, lack of risk perception, restlessness nurse ✓ 1
Impaired balance, gait disturbance nurse ✓ 1
Occurrence of dizziness and drowsiness nurse ✓ 1
Table 3 Characteristics of the participants from two health care institutions included in the study (n = 188, of which hospital
inpatients, n = 128; nursing home residents, n = 60)
Characteristics Hospital Nursing home Total
Sex n (%) Male 67 (52) 18 (30) 85 (45)
Female 61 (48) 42 (70) 103 (55)
Age, years, mean (range) 80 (60–97) 77 (63–95) 79 (60–97)
MMSE, mean (range) 21.7 (5–30) unknown –
Length of stay, days, mean (range) 15.8 (1–56) permanent –
Number of drugs in use, mean (range) 10.0 (3–17) 7.8 (2–15) 9.3 (2–17)
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for the nervous system (53%, n = 375) and the cardiovas-
cular system (40%, n = 281) (Fig. 1). The nervous system
medicines in use were mainly psychotropic medications
(73% of the medicines in use in this category), while an-
algesics (16%), antiepileptics (8%) and antiparkinson
drugs (3%) represented a minority. Psychotropic medica-
tions (n = 274) consisted of 1) psycholeptics (n = 179,
representing 65% of the medicines in this category) such
as antipsychotics (n = 109, 40%), anxiolytics (n = 55,
20%), hypnotics and sedatives (n = 15, 5%), and 2) psy-
choanaleptics (n = 95, representing 35% of the medicines
in this category) such as antidepressants (n = 65, 24%)
and anti-dementia drugs (n = 30, 11%). The high fall risk
cardiovacular medications (n = 281) included agents act-
ing on the renin-angiotension system (RAS) (n = 92, 33%
of the medicines in use in this category), beta blocking
Fig. 1 Categorization of high fall-risk Category A medicines (n = 710) according to therapeutic group and number of users. The medicines are
organized according to the ATC Classification [38].. Anatomical main group (1st level, dark grey), Therapeutic subgroup (2nd level, blue),
Pharmacological subgroup (3rd level, grey)
Table 4 Distribution of fall risk scores in fall-experienced patients (n = 188) using 4 fall risk items routinely assessed by nurses on
admission (each item yielding 1 point, score range 0–4). Medications were not included in the assessement
Scores Fall risk level Number of patients Proportion (%) of patients
0 No risk 5 3
1 Low risk 17 9
2 Medium risk 66 35
3 High risk 69 37
4 Full risk 31 16
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agents (n = 85, 30%), cardiac therapy (n = 54, 19%),
calcium channel blockers (n = 27, 10%) and other thera-
peutic subgroups (n = 23, 8%).
Of the 216 active substances used by the patients, 102
(47%) were classified in the high-risk category (fall risk
level A), 29 (13%) in the moderate risk category (fall risk
level B) and 85 (40%) in no risk category (fall risk level C).
The leading mechanisms of ADEs consequencing in high
fall risk of most commonly used active ingredients by study
participants are presented in Table 5. The most commonly
used active ingredients in the high fall risk category A (n =
710) are presented in Table 6, included metoprolol (n = 49,
beta blocking agents), perindopril (n = 38, ACE inhibitors),
tiapride (n = 36, antipsychotics), quetiapine (n = 24,
antipsychotics), tramadol (n = 24, opioids), citalopram
(n = 23, antipressants), amlodipine (n = 23, calcium
channel blockers), melperone (n = 23, antipsychotics),
bromazepam (n = 20, anxiolytics), digoxin (n = 18, cardiac
glycosides), and ramipril (n = 18, ACE inhibitors).
Discussion
This study developed a preliminary categorization to
identify medicines that may increase a fall risk in
older adults in institutions, by using evidence derived
from statutory medicines information and retrospect-
ive patient records. Our results indicate that numer-
ous medicines have such an ADE profile that can
lead to an increased fall risk and that the use of these
high fall-risk medicines, even concomitant use of
several active ingredients, is common in older adults
during a hospital stay or while living in a nursing
home. These findings suggest incorporating a
medication-related fall risk indicator in a routine fall
risk assessment on admission to geriatric care units.
In long-term care units such as nursing homes, it
may be useful to repeat the fall risk assessment regularly,
e.g., at least once a year.
The high-fall risk categorization presented in this
study considered also patient data which gives an idea
of the prevalence of clinical use of different medi-
cines. By this way it was possible to identify a few
widely used medicines with a high fall risk. The top
three clearly most commonly used high fall risk active
substances were metoprolol (beta blocking agent),
perindopril (ACE inhibitor) and tiapride (antipsychotic
agent). Of the top ten active ingredients, 6/10 were
psychotropics (3 of them antipsychotics) and 4/10
cardiovascular agents. Optimizing the use of these few
medicines in terms of prospectively managing fall risk
could make a remarkable change in the incidence of
actual falls in geriatric care units.
Our findings concerning the “ranking “of drugs with
a high fall risk are in line with previous research. The
association with falls has been consistently reported
for psychotropic and cardiovascular medicines [39–
45]. The recent systematic reviews and meta-analyses
(Seppala [43] and de Vries [44]) confirmed the associ-
ation between certain drug classes and fall risk from
psychotropics, i.e., antidepressants (OR = 1.57), anti-
psychotics (OR = 1.54), and benzodiazepines (OR =
1.42), and cardiovascular drugs, i.e., cardiac glycosides
(OR = 1.6), antiarrhythmics (OR = 1.27), vazodilatators
(OR = 1.03), and ACE inhibitors (OR = 1.03). The
increased fall risk is also evidenced in patients using
opioids (OR = 1.61), antiepileptics (OR = 1.55), anti-
Parkinson drugs (OR = 1.54), and NSAIDs (OR = 1.09)
Table 5 The most commonly used fall risk increasing drugs (Category A) having very common (≥1/10) or common (≥1/100)
frequency of ADEs connected to fall risk according to statutory summary of product characteristics (SmPCs)
Active ingredient (number of users) Drug class (ATC) Frequency of ADEs according to SmPCs
Metoprolol (n = 49) Beta blocking agents (C07A) Common: dizziness, bradycardia
Perindopril (n = 38) ACE inhibitors (C09A) Common: dizziness, orthostatic hypotension, syncope
Tiapride (n = 36) Antipsychotics (N05A) Common: dizziness, drowsiness
Quetiapine (n = 24) Antipsychotics (N05A) Very common: dizziness, drowsiness
Common: orthostatic hypotension
Tramadol (n = 24) Opioids (N02A) Very common: dizziness
Common: drowsiness
Citalopram (n = 23) Antidepressants (N06A) Very common: drowsiness
Common: dizziness
Amlodipine (n = 23) Calcium channel blockers (C08C) Common: dizziness, drowsiness
Melperon (n = 23) Antipsychotics (N05A) Very common: sedation
Common: dizziness
Bromazepam (n = 20) Anxiolytics (N05B) Common: drowsiness, fallsa
Digoxin (n = 18) Cardiac glycosides (C01A) Common: bradycardia, dizziness
Ramipril (n = 18) ACE inhibitors (C09A) Common: dizziness, orthostatic hypotension, syncope
aunknown frequency of ADE
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Table 6 The preliminary categorization of high fall risk medicines (Category A) basing on their adverse drug effect (ADE) profiles in
statutory summaries of product characteristics (SmPCs) and frequency of use in older patients who had experienced at least one
documented fall in a geriatric care unit (n = 188). The medicines are organized according to the ATC Classification [38]
High fall risk (A) ATC Code ATC classification Users of the medicines n (%)
Metoprolol C07AB02 Beta blocking agents 49 (26.1)
Perindopril C09AA04 ACE inhibitors 38 (20.2)
Tiapride N05AL03 Antipsychotics 36 (19.1)
Quetiapine N05AH04 Antipsychotics 24 (12.8)
Tramadol N02AX02 Opioids 24 (12.8)
Citalopram N06AB04 Antidepressants 23 (12.2)
Amlodipine C08CA01 Calcium channel blockers 23 (12.2)
Melperone N05AD03 Antipsychotics 23 (12.2)
Bromazepam N05BA08 Anxiolytics 20 (10.6)
Ramipril C09AA04 ACE inhibitors 18 (9.6)
Digoxin C01AA05 Cardiac glycosides 18 (9.6)
Tramadol combination N02AJ13 Opioids 16 (8.5)
Bisoprolol C07AB07 Beta blocking agents 16 (8.5)
Zolpidem N05CF02 Hypnotics and Sedatives 15 (8.0)
Donepezil N06DA02 Anti-dementia drugs 14 (7.4)
Mirtazapine N06AX11 Antidepressants 14 (7.4)
Amiodarone C01BD01 Antiarrhythmics 14 (7.4)
Oxazepam N05BA04 Anxiolytics 14 (7.4)
Tamsulosin G04CA02 Urologicals 14 (7.4)
Memantine N06DX01 Anti-dementia drugs 12 (6.4)
Diazepam N05BA01 Anxiolytics 11 (5.9)
Gabapentin N03AX12 Antiepileptics 11 (5.9)
Trazodone N06AX05 Antidepressants 10 (5.3)
Isosorbide mononitrate C01DA14 Vasodilatators 10 (5.3)
Clonazepam N03AE01 Antiepileptics 10 (5.3)
Codein combination N02AJ06 Opioids 9 (4.8)
Risperidone N05AX08 Antipsychotics 8 (4.3)
Losartan C09CA01 AT II receptor blockers 8 (4.3)
Sertraline N06AB06 Antidepressants 7 (3.7)
Levodopa N04BA01 Dopaminergic agents 7 (3.7)
Aminophylline R03DA05 Drugs for obstructive airway diseases 7 (3.7)
Carvedilol C07AG02 Beta blocking agents 7 (3.7)
Fentanyl N02AB03 Opioids 6 (3.2)
Rosuvastatin C10AA07 Lipid modifying agents 6 (3.2)
Betaxolol C07AB05 Beta blocking agents 6 (3.2)
Haloperidol N05AD01 Antipsychotics 6 (3.2)
Levomepromazine N05AA02 Antipsychotics 6 (3.2)
Pregabalin N03AX16 Antiepileptics 6 (3.2)
Nitrofurantoin J01XE01 Antibacterials for systemic use 6 (3.2)
Urapidil C02CA06 Antiadrenergic agents 5 (2.7)
Rilmenidine C02AC06 Antiadrenergic agents 5 (2.7)
Nebivolol C07AB12 Beta blocking agents 5 (2.7)
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Table 6 The preliminary categorization of high fall risk medicines (Category A) basing on their adverse drug effect (ADE) profiles in
statutory summaries of product characteristics (SmPCs) and frequency of use in older patients who had experienced at least one
documented fall in a geriatric care unit (n = 188). The medicines are organized according to the ATC Classification [38] (Continued)
High fall risk (A) ATC Code ATC classification Users of the medicines n (%)
Escitalopram N06AB10 Antidepressants 5 (2.7)
Telmisartan C09CA07 AT II receptor blockers 5 (2.7)
Midazolam N05CD08 Hypnotics and Sedatives 5 (2.7)
Alprazolam N05BA12 Anxiolytics 5 (2.7)
Perindopril/Indapamide C09BA04 ACE inhibitors combination 5 (2.7)
Verapamil C08DA01 Calcium channel blockers 4 (2.1)
Amiloride/Hydrochlorthiazide C03EA01 Diuretics 4 (2.1)
Rivastigmine N06DA03 Anti-dementia drugs 4 (2.1)
Olanzapine N05AH03 Antipsychotics 4 (2.1)
Dutasteride/Tamsulosin G04CA52 Urologicals 4 (2.1)
Trimetazidine C01EB15 Other cardiac preparations 4 (2.1)
Fosinopril C09AA09 ACE inhibitors 3 (1.6)
Isosorbide dinitrate C01DA08 Vasodilatators 3 (1.6)
Aceclofenac M01AB16 Anti-inflammatory drugs 3 (1.6)
Captopril C09AA01 ACE inhibitors 3 (1.6)
Baclofen M03BX01 Muscle relaxants 3 (1.6)
Lansoprazole A02BC03 Drug for peptic ulcer and reflux 3 (1.6)
Cefuroxime J01DC02 Antibacterials for systemic use 3 (1.6)
Levetiracetam N03AX14 Antiepileptics 2 (1.1)
Propafenone C01BC03 Antiarrhythmics 2 (1.1)
Carbamazepine N03AF01 Antiepileptics 2 (1.1)
Diclofenac M01AB05 Anti-inflammatory drugs 2 (1.1)
Solifenacin/Tamsulosin G04CA53 Urologicals 2 (1.1)
Oxycodone N02AA05 Opioids 2 (1.1)
Trandolapril C09AA10 ACE inhibitors 2 (1.1)
Levodopa/Carbidopa N04BA02 Dopaminergic agents 2 (1.1)
Perindopril/Amlodipine/Indapamide C09BX01 ACE inhibitors combination 2 (1.1)
Bicalutamide L02BB03 Hormone antagonists 2 (1.1)
Glyceryl trinitrate C01DA02 Vasodilatators 2 (1.1)
Fluoxetine N06AB03 Antidepressants 1 (0.5)
Dosulepin N06AA16 Antidepressants 1 (0.5)
Mianserin N06AX03 Antidepressants 1 (0.5)
Candesartan C09CA06 AT II receptor blockers 1 (0.5)
Venlafaxine N06AX16 Antidepressants 1 (0.5)
Telmisartan/Hydrochlorothiazide C09DA07 AT II receptor blockers combination 1 (0.5)
Tizanidine M03BX02 Muscle relaxants 1 (0.5)
Lisinopril C09AA03 ACE inhibitors 1 (0.5)
Famotidine A02BA03 Drug for peptic ulcer and reflux 1 (0.5)
Quinapril/Hydrochlorothiazide C09BA06 ACE inhibitors combination 1 (0.5)
Naftidrofuryl C04AX21 Peripheral vasodilatators 1 (0.5)
Celiprolol C07AB08 Beta blocking agents 1 (0.5)
Paroxetine N06AB05 Antidepressants 1 (0.5)
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[46, 47]. Furthermore, the previous study from Czech
Republic (Maly et al. [48]) classified drugs that affected to
the nervous system (antipsychotics, antidepressants, anal-
gesics) and to the cardiovascular system (diuretics, beta
blocking agents, agents acting on the renin-angiotensin
system) as the most frequently used fall risk-increasing
drugs in hospitals. Thus, many studies have reached
similar conclusions, although the fall-increasing medicines
have been presented slightly in different order. The identi-
fication of increased risk of falls in different drug classes
might be a crucial risk factor for falls. The European
Geriatric Medicine Society and Finnish Expert Group on
Fall-Risk-Increasing Drugs (FRIDs) have concluded that
the knowledge about the risk of falls associated with
therapeutic classes and individual medications can help in
fall prevention [49].
According to our findings, the fall risk assessment tool
presented in this study could be helpful to prevent
medication-related falls and increase quality of geriatric
care in health care institutions. This is supported by the
findings of previous studies that have reported the medi-
cation use as a remarkable but modifiable fall risk factor
[48, 50]. Therefore, it is reasonable to implement a
strategy to avoid use of fall risk-increasing drugs in the
routine practice in geriatric care units. Nevertheless,
many of developed fall risk assessment tools do not
consider medication as a risk factor included in the tool.
A review of twenty fall risk assessment tools found that
only seven of the tools consider medication use as a risk
factor [32]. More recent tools include medication use in
a fall risk assessment, e.g., The Johns Hopkins Fall Risk
Assessment Tool: it ranks opiates, anticonvulsants, anti-
hypertensives, diuretics, hypnotics, laxatives, sedatives,
and psychotropics among high fall risk drugs [51].The
Johns Hopkins Fall Risk Assessment Tool is well-
structured and validated, but the total number of risk
points to evaluate is high (maximum 28). This makes it
more time consuming for health care providers to assess
the fall risk than by using a tool with fewer risk points,
such as the five items suggested to be used in our updated
fall risk assessment tool. Our tool is also unique in the
way that the list of fall risk medicines was created basing
on statutory medicines information presented in the
summaries of product characteristics approved by
European Union (EU) authorities.
This study indicates that the current practice of fall
risk estimation in geriatric care units without includ-
ing medications underestimates the actual fall risk.
More than half (53%, n = 100) of the patients included
in our study scored at least a high fall risk, but the
remaining 46% (n = 88) of these fall-experienced pa-
tients scored a medium risk (35%), a low risk (9%) or
no risk (3%). The addition of a new item scoring the
exposure to the high fall risk medication could refine
the prospective risk assessments. This new risk item
represented by high fall risk medicines (FRIDs) should
Table 6 The preliminary categorization of high fall risk medicines (Category A) basing on their adverse drug effect (ADE) profiles in
statutory summaries of product characteristics (SmPCs) and frequency of use in older patients who had experienced at least one
documented fall in a geriatric care unit (n = 188). The medicines are organized according to the ATC Classification [38] (Continued)
High fall risk (A) ATC Code ATC classification Users of the medicines n (%)
Methyldopa C02AB01 Antiadrenergic agents 1 (0.5)
Tianeptine N06AX14 Antidepressants 1 (0.5)
Doxazosin C02CA04 Antiadrenergic agents 1 (0.5)
Ticagrelor B01AC24 Antithrombotic agents 1 (0.5)
Losartan/Hydrochlorothiazide C09DA01 ACE inhibitors combination 1 (0.5)
Codeine R05DA04 Cough suppressants 1 (0.5)
Acebutolol C07AB04 Beta blocking agents 1 (0.5)
Mirabegron G04BD12 Urologicals 1 (0.5)
Ibandronic acid M05BA06 Drugs affecting bone 1 (0.5)
Levodopa/Benserazide N04BA02 Dopaminergic agents 1 (0.5)
Selegiline N04BD01 Dopaminergic agents 1 (0.5)
Moxonidine C02AC05 Antiadrenergic agents 1 (0.5)
Irbesartan C09CA04 ACE inhibitors 1 (0.5)
Perindopril/Amlodipine C09BB04 ACE inhibitors combination 1 (0.5)
Cilazapril C09AA08 ACE inhibitors 1 (0.5)
Fluphenazine N05AB02 Antipsychotics 1 (0.5)
Ropinirole N04BC04 Dopaminergic agents 1 (0.5)
Chlorprothixene N05AF03 Antipsychotics 1 (0.5)
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be considered in each patient admission or medica-
tion change and periodically assessed in the existing
fall risk assessment tool by health care experts.
Fine-tuning the fall risk scoring system requires fur-
ther research and comparisons with the contents of
other existing tools. Further research should compare
how much adding high risk medicines to the fall risk
assessment tool changes the risk score and makes the
risk score more accurate in terms of predicting and
preventing actual falls. It also might be useful to assess
whether concomitant use of more than one FRID
medicines will elevate the fall risk. Determining this in
future studies may be necessary because the concomi-
tant use of several drugs that increase the risk of falls
was common in our data (on average 3.8 high risk
medicaments per patient). In addition to this kind of risk
verification research, more generalizable results are
needed by testing the fall risk assessment tool with a larger
number of geriatric patients from a larger number of
hospital wards and nursing homes. These studies should
be based on prospective patient data. Furthermore, the fall
risk profiles and patterns of the high fall risk medicines
should be further investigated in older adults in hospital
and home care settings.
Study limitations
When interpreting the results of this study it is import-
ant to keep in mind that the study does not cover the
complete spectrum of medicines used by older adults,
only the medicines used by the 188 study patients.
Furthermore, the retrospective patient and medication
data from the patient records may perform as a source
of bias. The data related to the nursing home residents
were not documented in such detail compared to that
of hospital patients. The differences in the detailed-
ness of documentation concern e.g., information on
cognitive impairment or changes made to medications of
individual patients. Documentation may have missed
minor falls which were not reported to the staff by the
patients.
Conclusion
It was possible to develop a preliminary categorization
of FRIDs basing on their adverse drug effect profile in
SmPCs and frequency of use in older patients who had
experienced at least one documented fall in a geriatric
care unit. Even though more than half of the fall-
experienced older adults had at least high fall risk scores
on admission according to the fall risk items routinely
assessed, their fall risk might have been underestimated as
use of high fall risk medicaments was common, even
concomitant use. Further studies are needed to develop
the FRID categorization and assess its impact on fall risk.
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